We read with interest the article entitled ''Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction'' by Kundi et al. 1 They showed that high endocan levels during hospital admission are an independent predictor of a worse cardiovascular (CV) outcome and a high SYNTAX score in patients with ST-segment elevation myocardial infarction.
Endocan is an immunoinflammatory marker linked to endothelial dysfunction and may be a predictor of CV disease events. 2,3 Also, Cimen et al 4 found that endocan levels in patients with microvascular angina were higher than that of the control group. Besides, Cimen et al 4 excluded patients with the conditions such as acute coronary syndrome, history of previous myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, secondary hypertension, severe valvular disease, congestive heart failure (New York Heart Association Classes III-IV), renal and hepatic dysfunction, any active inflammatory disease, atrial fibrillation, and malignancy. However, Kundi et al 1 do not report any data about exclusion criteria in the study patients. They specified that only 9 patients were excluded because percutaneous coronary intervention was not performed. Likewise, hypertension rate was significantly different between the 2 groups. Hypertension is a major factor that can be associated with inflammation. 5 We think that the authors should add this variable to the multivariate analysis.
